Skip to main content
JIN YANG PHARMACEUTICAL. CO., LTD logo

JIN YANG PHARMACEUTICAL. CO., LTD — Investor Relations & Filings

Ticker · 007370 ISIN · KR7007370000 KO Manufacturing
Open in API
Filings indexed 210 across all filing types
Latest filing 2025-07-08 Transaction in Own Shar…
Country KR South Korea
Listing KO 007370

About JIN YANG PHARMACEUTICAL. CO., LTD

https://www.jinyangpharm.com/

JIN YANG PHARMACEUTICAL. CO., LTD. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products, with a primary focus on prescription drugs. The company operates a fully automated, high-tech manufacturing facility. Its research and development efforts are dedicated to creating advanced preventive and therapeutic treatments for various diseases. Key areas of R&D include the development of anticancer drugs through molecular biology research, particularly for leukemia, and therapies for metabolic disorders such as diabetes and obesity. The company also develops antivirals and explores formulations based on herbal preparations.

Recent filings

Filing Released Lang Actions
주요사항보고서(자기주식취득신탁계약해지결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding the termination of a treasury stock trust contract (자기주식취득 신탁계약 해지 결정). This involves the company's own shares and falls under the category of share repurchase or related capital changes. According to the provided definitions, 'Transaction in Own Shares' (POS) is the correct classification for reports concerning the buying back or selling of a company's own shares.
2025-07-08 Korean
주요사항보고서(자기주식취득신탁계약해지결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean financial authorities (Financial Services Commission/Korea Exchange) regarding the termination of a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 해지 결정). This falls under the category of company share buyback or treasury share management activities. According to the provided definitions, 'Transaction in Own Shares' (POS) is the correct classification for reports concerning the company buying back or selling its own shares.
2025-07-08 Korean
신탁계약해지결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on the Termination of a Trust Agreement' (신탁계약해지결과보고서) filed by Jinyang Pharmaceutical. It details the termination of a trust contract used for share repurchases and provides a breakdown of the company's treasury stock holdings before and after the termination. This type of filing is a standard regulatory disclosure regarding a company's own share transactions (buybacks/cancellations/trust terminations). In the provided taxonomy, 'POS' (Transaction in Own Shares) is the most accurate category for reports concerning the acquisition, disposal, or trust-based management of a company's own shares.
2025-07-08 Korean
신탁계약해지결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '신탁계약해지결과보고서' (Report on the Termination of a Trust Agreement) filed with the Financial Supervisory Service (FSS) in South Korea. It details the termination of a share repurchase trust contract and the resulting status of the company's treasury shares. This falls under the category of 'Transaction in Own Shares' (POS), as it reports the conclusion of a share buyback program and the subsequent holding status of the company's own shares.
2025-07-08 Korean
신탁계약해지결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '신탁계약해지결과보고서' (Report on the Termination of a Trust Agreement) filed with the Financial Supervisory Service (FSS) in South Korea. It details the termination of a trust contract related to the company's own shares (treasury shares). According to the filing definitions, documents reporting the company's buyback or sale of its own shares, including the termination of trust agreements used for such purposes, fall under the 'Transaction in Own Shares' category.
2025-07-08 Korean
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from Jinyang Pharmaceutical regarding the decision to dispose of treasury shares (자기주식 처분 결정). This is a regulatory filing required by the Korea Exchange (KRX) for corporate actions involving share buybacks or disposals. Since the document details the company's decision to sell its own shares, it falls under the category of 'Transaction in Own Shares'.
2025-07-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.